Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination.
Contamination of platelet units by bacteria has long been acknowledged as a significant transfusion risk due to their post-donation storage conditions. Products are routinely stored at 22 °C on an agitating shaker, a condition that can promote bacterial growth. Although the total number of bacteria believed to be introduced into a platelet product is extremely low, these bacteria can multiply to a very high titer prior to transfusion, potentially resulting in serious adverse events. The aim of this study was to evaluate a riboflavin based pathogen reduction process against a panel of bacteria that have been identified as common contaminants of platelet products. This panel included the following organisms: S. epidermidis, S. aureus, S. mitis, S. pyogenes, S. marcescens, Y. enterocolitica, B. neotomae, B. cereus, E. coli, P. aeruginosa and K. pneumoniae. Each platelet unit was inoculated with a high bacterial load and samples were removed both before and after treatment. A colony forming assay, using an end point dilution scheme, was used to determine the pre-treatment and post-treatment bacterial titers. Log reduction was calculated by subtracting the post-treatment titer from the pre-treatment titer. The following log reductions were observed: S. epidermidis 4.7 log (99.998%), S. aureus 4.8 log (99.998%), S. mitis 3.7 log (99.98%), S. pyogenes 2.6 log (99.7%), S. marcescens 4.0 log (99.99%), Y. enterocolitica 3.3 log (99.95%), B. neotomae 5.4 log (99.9996%), B. cereus 2.6 log (99.7%), E. coli ≥5.4 log (99.9996%), P. aeruginosa 4.7 log (99.998%) and K. pneumoniae 2.8 log (99.8%). The results from this study suggest the process could help to lower the risk of severe adverse transfusion events associated with bacterial contamination.
Terumo BCT, Scientific Affairs; shawn.keil@terumobct.com.
Shawn D
SD
Keil
Terumo BCT, Scientific Affairs.
Nick
N
Hovenga
Terumo BCT, Scientific Affairs.
Denise
D
Gilmour
Terumo BCT, Scientific Affairs.
Susanne
S
Marschner
Terumo BCT, Scientific Affairs.
Raymond
R
Goodrich
D001792:Blood Platelets / Q000187:drug effects / Q000382:microbiology* / Q000528:radiation effects; D015169:Colony Count, Microbial / Q000379:methods; D006801:Humans; D017713:Platelet Transfusion / Q000379:methods; D012256:Riboflavin / Q000494:pharmacology*; D014466:Ultraviolet Rays
D012256:Riboflavin